देश: कनाडा
भाषा: अंग्रेज़ी
स्रोत: Health Canada
INFLIXIMAB
JANSSEN INC
L04AB02
INFLIXIMAB
100MG
POWDER FOR SOLUTION
INFLIXIMAB 100MG
INTRAVENOUS
100
Prescription
DISEASE-MODIFYING ANTIRHEUMATIC AGENTS
Active ingredient group (AIG) number: 0144162001; AHFS:
APPROVED
2020-12-29
Non-Ann PM OMV SNDS 269476 12152022.docx_ _ _EDMS-RIM-718584 v4.0 _ _Page 1 of 124 _ PRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION PR OMVYENCE ™ Infliximab for injection Powder for Solution, Sterile, Lyophilized, 100 mg/vial, Intravenous Infusion Biological Response Modifier Janssen Inc. 19 Green Belt Drive Toronto, Ontario M3C 1L9 www.janssen.com/canada Date of Initial Authorization: February 18, 2021 Date of Revision: Submission Control No: 269476 All trademarks used under license. © 2022 Janssen Inc. Non-Ann PM OMV SNDS 269476 12152022.docx_ _ _EDMS-RIM-718584 v4.0 _ _Page 2 of 124 _ RECENT MAJOR LABEL CHANGES 4 DOSAGE AND ADMINISTRATION, 4.1 Dosing Considerations 04/2021 4 DOSAGE AND ADMINISTRATION, 4.4 Administration 04/2021 7 WARNINGS AND PRECAUTIONS, Live Vaccines/Therapeutic Infectious Agents 12/2022 7 WARNINGS AND PRECAUTIONS, Fertility 05/2022 7 WARNINGS AND PRECAUTIONS, 7.1.1 Pregnant Women 05/2022 7 WARNINGS AND PRECAUTIONS, 7.1.2 Breast-feeding 12/2022 TABLE OF CONTENTS SECTIONS OR SUBSECTIONS THAT ARE NOT APPLICABLE AT THE TIME OF AUTHORIZATION ARE NOT LISTED. RECENT MAJOR LABEL CHANGES ....................................................................................... 2 TABLE OF CONTENTS ............................................................................................................ 2 PART I: HEALTH PROFESSIONAL INFORMATION ................................................................ 4 INDICATIONS ................................................................................................................ 4 1.1 Pediatrics .............................................................................................................. 5 1.2 Geriatrics .............................................................................................................. 5 CONTRAINDICATIONS ................................................................................................. 5 SERIOUS WARNINGS AND PRECAUTIONS BOX .................................................. पूरा दस्तावेज़ पढ़ें